Abstract
Epigenetic changes play an important role in cancer pathogenesis. Hypermethylation of DNA generally results in decreased expression of tumor suppressor genes and defective cell cycle control. This is a hallmark of myelodysplastic syndromes (MDS) and acute myeloid leukemia. Fortunately, epigenetic changes are potentially reversible and thus remain an attractive target for anticancer therapy. Inhibitors of DNA methyltransferase cause demethylation of DNA and exert their activity in myelodysplastic syndromes and acute myeloid leukemia with good safety profile. Decitabine and azacytidine are approved for treatment of patients with high-risk MDS. Demethylating agents seem to be the best choice for elderly patients with myelodysplastic syndromes and acute myeloid leukemia, even in case of high risk cytogenetic changes in the karyotype. The mechanisms of action, pharmacokinetics and antileukemic activity of azacytidine and decitabine are the subjects of this review.
Keywords: Myelodysplastic syndromes, acute myeloid leukemia, hypomethylating agents, azacytidine, decitabine, elderly, Cancer and Leukemia Group B, graft versus host reaction, graft versus leukemia effect, myelodysplastic syndrome
Current Cancer Drug Targets
Title: Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia
Volume: 11 Issue: 7
Author(s): Anna Szmigielska-Kaplon and Tadeusz Robak
Affiliation:
Keywords: Myelodysplastic syndromes, acute myeloid leukemia, hypomethylating agents, azacytidine, decitabine, elderly, Cancer and Leukemia Group B, graft versus host reaction, graft versus leukemia effect, myelodysplastic syndrome
Abstract: Epigenetic changes play an important role in cancer pathogenesis. Hypermethylation of DNA generally results in decreased expression of tumor suppressor genes and defective cell cycle control. This is a hallmark of myelodysplastic syndromes (MDS) and acute myeloid leukemia. Fortunately, epigenetic changes are potentially reversible and thus remain an attractive target for anticancer therapy. Inhibitors of DNA methyltransferase cause demethylation of DNA and exert their activity in myelodysplastic syndromes and acute myeloid leukemia with good safety profile. Decitabine and azacytidine are approved for treatment of patients with high-risk MDS. Demethylating agents seem to be the best choice for elderly patients with myelodysplastic syndromes and acute myeloid leukemia, even in case of high risk cytogenetic changes in the karyotype. The mechanisms of action, pharmacokinetics and antileukemic activity of azacytidine and decitabine are the subjects of this review.
Export Options
About this article
Cite this article as:
Szmigielska-Kaplon Anna and Robak Tadeusz, Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia, Current Cancer Drug Targets 2011; 11 (7) . https://dx.doi.org/10.2174/156800911796798940
DOI https://dx.doi.org/10.2174/156800911796798940 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Adrenomedullin and its Family Peptide by RAMP System – Lessons from Genetically Engineered Mice
Current Protein & Peptide Science Computational Studies in Drug Design Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot topic: Breast Cancer: Novel Therapeutic Targets (Guest Editor: George W. Yip)]
Recent Patents on Anti-Cancer Drug Discovery Heparanase: Structure, Biological Functions, and Inhibition by Heparin-Derived Mimetics of Heparan Sulfate
Current Pharmaceutical Design Recent Patents Relating To HCV Molecules Like Putative Targets For Therapeutic Intervention
Recent Patents on DNA & Gene Sequences Three-Dimensional Manufactured Supports for Breast Cancer Stem Cell Population Characterization
Current Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews Molecular Based Drug Targets for Idiopathic Pulmonary Fibrosis
Current Respiratory Medicine Reviews Angiogenesis Inhibition in the Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Comparative Study for the Aqeous Synthesis of New Generation of Diindolylmethanes Using L-Proline, K10 and Nano-Fe3O4 under Ultrasound Irradiation
Letters in Organic Chemistry The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment
Current Pharmaceutical Design <i>In Silico</i> Identification of Novel Flavonoids Targeting Epidermal Growth Factor Receptor
Current Drug Discovery Technologies Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery
Current Medicinal Chemistry MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Preparation and Physicochemical Characterization of Glyceryl Monoolein Bearing Cubosomes to Improve Vitamin E delivery into the Skin: A Proposal for Skin Cancer Prevention
Drug Delivery Letters A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus
Current Pharmaceutical Design Clinical Pharmacogenomics of Thiopurine S-methyltransferase
Current Clinical Pharmacology Homology Modelling of Human E1 Ubiquitin Activating Enzyme
Letters in Drug Design & Discovery